Andira Pharmaceuticals
Andira Pharmaceuticals is a global leader in cannabinoid therapeutics, focusing on innovative solutions for medical infection control and cancer. The company is dedicated to transforming healthcare through breakthrough pharmaceutical innovations, leveraging natural drug substances, and advancing a pipeline of therapeutics and medical devices targeting infections and oncology.
Industries
Nr. of Employees
small (1-50)
Andira Pharmaceuticals
Products
Silver‑cannabinoid antimicrobial wound dressing (advanced wound care device)
An advanced wound dressing incorporating a synergistic silver and cannabinoid formulation intended to provide broad‑spectrum antimicrobial protection and support wound healing in healthcare settings.
Topical antimicrobial formulation for surgical site infection prevention
A topical antimicrobial cream formulation intended to prevent surgical site infections through localized antimicrobial activity.
Transdermal cannabinoid therapy for early‑stage breast lesions
A transdermal cannabinoid‑based therapy formulated for localized adjuctive treatment of ductal carcinoma in situ (DCIS) using targeted skin delivery to maximize local efficacy while limiting systemic exposure.
Silver‑cannabinoid antimicrobial wound dressing (advanced wound care device)
An advanced wound dressing incorporating a synergistic silver and cannabinoid formulation intended to provide broad‑spectrum antimicrobial protection and support wound healing in healthcare settings.
Topical antimicrobial formulation for surgical site infection prevention
A topical antimicrobial cream formulation intended to prevent surgical site infections through localized antimicrobial activity.
Transdermal cannabinoid therapy for early‑stage breast lesions
A transdermal cannabinoid‑based therapy formulated for localized adjuctive treatment of ductal carcinoma in situ (DCIS) using targeted skin delivery to maximize local efficacy while limiting systemic exposure.
Services
Preclinical development partnerships with CROs
Collaborative execution of preclinical efficacy and safety studies via external CROs to support lead asset development.
Academic collaborative research agreements
Collaborative research programs with university laboratories to characterize pharmacology, validate efficacy in specialized models, and advance IND readiness.
Regulatory and clinical development planning
Preparation of regulatory submission strategies and clinical trial planning for device and drug pathways, including IND and device submissions.
Preclinical development partnerships with CROs
Collaborative execution of preclinical efficacy and safety studies via external CROs to support lead asset development.
Academic collaborative research agreements
Collaborative research programs with university laboratories to characterize pharmacology, validate efficacy in specialized models, and advance IND readiness.
Regulatory and clinical development planning
Preparation of regulatory submission strategies and clinical trial planning for device and drug pathways, including IND and device submissions.
Expertise Areas
- Antimicrobial development and AMR testing
- Medical device development for wound care and IV‑site products
- Transdermal oncology therapeutics
- Preclinical safety and GLP‑style validation studies
Key Technologies
- Silver‑cannabinoid antimicrobial platform
- Transdermal delivery and skin permeation enhancers
- Cannabinoid‑based therapeutic formulations
- Serial‑passaging AMR testing